Fulminant hepatic failure in association with quetiapine: a case report

Journal of Medical Case Reports

Turki Al Ameel¹  Girish Dwivedi²  Fawaz Al Mutairi² 

[1] Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada;University of Ottawa Heart Institute, Ottawa, Ontario, Canada

关键词: Quetiapine;    Fulminant hepatic failure;    Acute liver injury;   

Others  :  1195191
DOI  :  10.1186/1752-1947-6-418

 received in 2012-03-21, accepted in 2012-11-04,  发布年份 2012

【 摘 要 】

Introduction

Fulminant hepatic failure is a serious disease with significant mortality and morbidity. Identifying the exact cause of hepatic failure and predicting prognosis is of paramount importance in managing such patients. Drug-induced liver injury is a common but challenging entity to treat. The use of newer drugs and medications with previously unknown hepatotoxicity add to the challenges faced by treating physicians. Quetiapine is an antipsychotic that has rarely been linked to acute liver injury. In the present work we describe a case of fulminant hepatic failure secondary to use of quetiapine.

Case presentation

A 59-year-old Caucasian woman with known Parkinson’s disease was being treated with quetiapine for hallucinations. She was referred to our hospital with yellow discoloration of the sclera and later on developed clinical features suggestive of hepatic encephalopathy. A diagnosis of fulminant hepatic failure was made following her admission to the intensive care unit. Her condition improved after discontinuing the drug and providing the standard supportive treatment.

Conclusions

Our findings in the present report emphasize the importance of keeping an open mind in cases of fulminant hepatic failure. As drug-induced hepatotoxicity is the most common cause of fulminant hepatic failure in many parts of the world, consideration should be given to the medication(s) patients receive as the potential cause and a review of this list should be part of the clinical care given.

【 授权许可】

   
2012 Al Mutairi et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Trey C, Davidson LS: The management of fulminant hepatic failure. In Prognosis in Liver Disease. Edited by Popper H, Shaffiner F. Grune and Stratton, New York, NY; 1970:282.
• [2]Bernauau J, Reuff B, Benhamou JP: Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis 1986, 6:97.
• [3]Hoofnagle JH, Carithers RL Jr, Shapiro C, Ascher N: Fulminant hepatic failure: summary of a workshop. Hepatology 1995, 21:240-252.
• [4]Schiodt FV, Atillasoy E, Shakil AO, Schiff ER, Caldwell C, Kowdley KV, Stribling R, Crippin JS, Flamm S, Somberg KA, Rosen H, McCashland TM, Hay JE, Lee WM: Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg 1999, 5:29-34.
• [5]Lacy C, Armstrong L, Goldman M, Lance L: Quetiapine. In Drug Information Handbook. 9th edition. Lexi-comp Inc, Hudson, OH; 2001:1046-1047.
• [6]Mullen J, Jibson MD, Sweitzer D: A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001, 23:1839-1854.
• [7]Iraqi A: A case report of pancytopenia with quetiapine use. Am J Geriatr Psychiatry 2003, 11:694.
• [8]Huynh M, Chee K, Lau DH: Thrombotic thrombocytopenic purpura associated with quetiapine. Ann Pharmacother 2005, 39:1346-1348.
• [9]Bourgeois JA, Babine S, Meyerovich M, Doyle J: A case of neuroleptic malignant syndrome with quetiapine. J Neuropsychiatry Clin Neurosci 2002, 14:87.
• [10]Alexiadis M, Whitehorn D, Woodley H, Kopala L: Prolactin elevation with quetiapine. Am J Psychiatry 2002, 159:1608-1609.
• [11]Velayudhan L, Kirchner V: Quetiapine-induced myoclonus. Int Clin Psychopharmacol 2005, 20:119-120.
• [12]Gajwani P, Pozuelo L, Tesar GE: QT interval prolongation associated with quetiapine (Seroquel) overdose. Psychosomatics 2000, 41:63-65.
• [13]El Hajj I, Sharara AI, Rockey DC: Subfulminant liver failure associated with quetiapine. Eur J Gastroenterol Hepatol 2004, 16:1415-1418.
• [14]Naharci MI, Karadurmus N, Demir O, Bozoglu E, Ak M, Doruk H: Fatal hepatotoxicity in an elderly patient receiving low-dose quetiapine. Am J Psychiatry 2011, 168:212-213.
• [15]Shpaner A, Li W, Ankoma-Sey V, Botero RC: Drug-induced liver injury: hepatotoxicity of quetiapine revisited. Eur J Gastroenterol Hepatol 2008, 20:1106-1109.
• [16]McConville BJ, Arvanitis LA, Thyrum PT, Yeh C, Wilkinson LA, Chaney RO, Foster KD, Sorter MT, Friedman LM, Brown KL, Heubi JE: Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 2000, 61:252-260.
• [17]Zeneca Pharma Ltd: Quetiapine (seroquel). Product monograph. Zeneca, London, UK; 1998:1-25.
• [18]Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM, US Acute Liver Failure Study Group: Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002, 137:947-954.
• [19]Bénichou C: Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990, 11:272-276.
• [20]Larrey D: Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002, 22:145-155.
• [21]Danan G, Benichou C: Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993, 46:1323-1330.
• [22]O’Grady JG, Alexander GJ, Hayllar KM, Williams R: Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989, 97:439-445.